Akebia Therapeutics, Inc. (AKBA) Stock Total Returns
Growth of $10,000 chart
2021-04-14 to 2026-04-14 to
$
%
%
Loading chart…
Investment Performance
Final Value
$5,008
Total Return
-49.92%
CAGR
-12.92%
Dividends
$0.00
Yield on Cost
0.00%
Rolling Returns
1-Month (21 Trading Days)
| Average | +2.97% |
| Median | -1.19% |
| Best | +129.46% |
| Worst | -82.79% |
| % of Windows Positive | 47.9% |
1-Year (252 Trading Days)
| Average | +53.28% |
| Median | +26.05% |
| Best | +370.59% |
| Worst | -91.79% |
| % of Windows Positive | 60.8% |
3-Year (756 Trading Days)
| Average | +237.78% |
| Median | +39.99% |
| Best | +1088.42% |
| Worst | -76.64% |
| % of Windows Positive | 56.2% |
Risk Metrics
| Maximum Drawdown | -94.05% |
| Average Drawdown | -59.31% |
| Drawdown Duration | 1204 Trading Days (Unrecovered) |
| Sortino Ratio | 0.49 |
| Calmar Ratio | -0.14 |
| CVaR (5%) | -12.37% |
Yearly Returns
| Year | Percentage | Abs. Return | Dividends | Taxes | Trans. Costs |
|---|---|---|---|---|---|
| 2026 partial | -3.11% (-10.49% ann.) | $310.56 | $0.00 | $0.00 | $0.00 |
| 2025 | -15.26% | $1526.26 | $0.00 | $0.00 | $0.00 |
| 2024 | +53.22% | +$5322.38 | $0.00 | $0.00 | $0.00 |
| 2023 | +114.90% | +$11490.17 | $0.00 | $0.00 | $0.00 |
| 2022 | -74.47% | $7446.85 | $0.00 | $0.00 | $0.00 |
| 2021 | -19.29% | $1928.61 | $0.00 | $0.00 | $0.00 |
| 2020 | -55.70% | $5569.59 | $0.00 | $0.00 | $0.00 |
| 2019 | +14.29% | +$1428.54 | $0.00 | $0.00 | $0.00 |
| 2018 | -62.81% | $6281.10 | $0.00 | $0.00 | $0.00 |
| 2017 | +42.84% | +$4284.33 | $0.00 | $0.00 | $0.00 |
| 2016 | -19.43% | $1942.72 | $0.00 | $0.00 | $0.00 |
| 2015 | +11.00% | +$1099.65 | $0.00 | $0.00 | $0.00 |
| 2014 partial | -56.40% (-65.36% ann.) | $5639.63 | $0.00 | $0.00 | $0.00 |
Market Regimes
| Regime | Period | Percentage | Annual | Abs. Return | Dividends | Taxes | Trans. Costs |
|---|---|---|---|---|---|---|---|
| Secular stagnation / QE / low inflation / duration bull partial | March 20, 2014 – February 19, 2020 | -63.70% | -15.73% | $6370.11 | $0.00 | $0.00 | $0.00 |
| Pandemic shock / liquidity crash | February 20, 2020 – March 23, 2020 | -39.16% | -99.66% | $3916.01 | $0.00 | $0.00 | $0.00 |
| Policy bazooka / monetary euphoria | March 24, 2020 – November 6, 2020 | -67.13% | -83.31% | $6712.72 | $0.00 | $0.00 | $0.00 |
| Reopening reflation / fiscal boom / supply bottlenecks | November 9, 2020 – November 29, 2021 | +6.94% | +6.57% | +$693.96 | $0.00 | $0.00 | $0.00 |
| Inflation shock / duration crash / aggressive tightening | November 30, 2021 – November 9, 2022 | -90.59% | -91.87% | $9059.07 | $0.00 | $0.00 | $0.00 |
| Disinflation rebound / AI-led narrow bull / higher-for-longer | November 10, 2022 – September 17, 2024 | +400.00% | +138.29% | +$40000.00 | $0.00 | $0.00 | $0.00 |
| Disinflationary easing / resilient growth / AI capex under oil-shock test partial | September 18, 2024 – April 14, 2026 | +15.56% | +9.65% | +$1555.63 | $0.00 | $0.00 | $0.00 |
Dividend History
| Date | Per Share | Yield % |
|---|---|---|
| Total | 0 payments |
No dividends recorded.
All calculations use split-adjusted closing prices. Dividends are reinvested on the ex-dividend date at that day's closing price.
For each rolling window, returns are calculated at every possible starting point:
return = (value[i] ÷ value[i − windowSize] − 1) × 100
- Windows
- 1-month = 21 trading days, 1-year = 252 trading days, 3-year = 756 trading days.
- Statistics
- Average: arithmetic mean. Median: middle value when sorted. Best / Worst: max and min. % Positive: share of windows with return > 0.
The series is segmented by calendar year:
return = (endValue ÷ startValue − 1) × 100
startValue is the last value of the prior year (or the first value for the initial year). Partial first/last years are flagged. Dividends, taxes, and transaction costs are scaled proportionally to the initial investment.